cyrilzakka/clinical-trials huggingface dataset:
PET-MRI Esophagus Feasibility Study

This is a single arm, single centre, investigator initiated study to investigate the feasibility of using PET-MRI imaging in radiation treatment workflow in up to 15 patients with esophagogastric cancer. PET-MRI imaging will be completed before the start of radiation treatment. MRI imaging will be completed during radiation treatment and after radiation treatment. These images will not be used to plan the radiation treatment and routine clinical care will be provided.

The goal of this study is to gather information that will allow the radiation team to include MRI and PET imaging into the radiation treatment workflow for patients with esophageal cancer receiving radiation therapy in the future.


Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years or older
* Diagnosed with locally advanced esophageal cancer being considered for conventional RT \>4 weeks
* Ability and willingness to provide written informed consent

Exclusion Criteria:

* Contraindication for MRI
* Contraindication for Gadolinium (i.e. inability to lie supine for at least 60 minutes)
* Any patient who is pregnant or breastfeeding
* Pacemaker or implanted defibrillator
* Claustrophobia
Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers

Our goal is to demonstrate that healthy volunteers treated with fenobam will develop a significantly reduced area of cutaneous hyperalgesia compared to volunteers treated with placebo, after exposure to the heat/capsaicin model of cutaneous sensitization. Additionally we are going to assess changes in mood/affect and cognitive function of subjects following administration of fenobam and after cutaneous sensitization compared to baseline.

All subjects will receive a topical dose of capsaicin cream 0.1%(Capzasin-HP) to the forearm at the start of the study visit. The order of the 2 treatment regimens indicated below will be randomized and blinded to subjects and researchers.

Treatment Regimen 1: Fenobam \[1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate\]: administration of one 150 mg gelatin capsule.

Treatment Regimen 2: Placebo (lactose monohydrate): administration of one 150 mg gelatin capsule.

Eligibility Criteria:
Inclusion Criteria:

1. 18-50 year old
2. Good general health with no remarkable medical conditions (e.g. liver, kidney, heart, or lung failure)
3. BMI between 20-33
4. Willing to comply with study guidelines as outlined in protocol \[including: women of childbearing age must be willing to use a double-barrier method (e.g. oral contraception and condom) for contraception during participation in the study\]
5. Willing to provide informed consent

Exclusion Criteria:

1. Anatomical malformation of upper extremities
2. Status post recent trauma or chronic lesions on either forearm
3. Medication use (includes vitamin, herbal, dietary and mineral supplements and grapefruit products during or within 14 days prior to study participation; excludes contraceptives)
4. History of allergy or intolerance to capsaicin
5. History of multiple drug allergies
6. History of addiction to drugs or alcohol (prior or present addiction or treatment for addiction)
7. History of chronic pain syndromes
8. Pregnant and nursing females
9. Smokers
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients older than 18 years
* With a diagnosis of schizophrenia (DSM-IV TR criteria)
* Stabilized out-patients
* Under oral antipsychotic monotherapy

Exclusion Criteria:

* Administration of a depot antipsychotic drug
* Suicide risk
RAKT OUTCOME ANALYSIS

The goal of this observational study is to compare outcomes of robot-assisted kidney transplantation and open kidney transplantation. The main questions are

- comprehensively analyze our early experience of robot-assisted kidney transplant patients and compare the results with those of open kidney transplant patients


Eligibility Criteria:
Inclusion Criteria:

* Patients received kidney transplantation in SeoulNUH between Jan 2018 and Jan 2024

Exclusion Criteria:

* patients with multi-organ transplant
* patients with missing operative data
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers

SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and Pharmacokinetics profiles of SP2086 in healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

* BMI(a measure of a person's weight in relation to height)is between 19 and 26 kg/m2,and the weight is equal or less than 100kg.
* without the history of cardiovascular diseases,liver diseases,kidney diseases,gastrointestinal tract diseases,mental nerve diseases and drug allergy.
* Be willing to accept physical contraception.
* Sign the informed consents voluntarily and ensure to completed the study.

Exclusion Criteria:

* Known allergy to SP2086 or any of the excipients of the formulation of SP2086;
* ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack.
* the B hepatitis surface antigen or hepatitis C antibody or syphilis antibody or HIV antibody was positive.
* had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening.
* have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening.
* have the history of tobacco,alcohol or drug abuse.
* History of or current clinically significant medical illness as determined by the Investigator.
SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine

The study question: Does the SNAP-Index (SI) correlates better with the OASS than the BIS Monitor during sedation with ketamine?

The study hypothesis: Since the SNAP II monitor seems to be more responsive during emergence of anesthesia, it will have a better correlation with the OASS than the BIS monitor with the use of ketamine.


Eligibility Criteria:
Inclusion Criteria:

* Age : 18-64 years
* ASA : I-III
* Procedure : Breast or gynecological surgery
* Anesthesia :Monitored anesthesia care

Exclusion Criteria:

* Pregnancy
* Breast Feeding
* Body Mass Index \>35kg/m2
* Drug or Alcohol abuse
* Use anticonvulsants
* History of CVA
* Drop-out criteria:

  * Patient or surgeon request
  * Conversion to general anesthesia
  * Inability to obtain data from both monitors
Comparing Virtual Reality Exposure Therapy to Prolonged Exposure

This study is evaluating the efficacy of virtual reality exposure therapy (VRET) by comparing it to prolonged exposure therapy (PE) and a waitlist(WL) group for the treatment of post traumatic stress disorder (PTSD) in active duty (AD) Soldiers with combat-related trauma. The investigators will test the general hypothesis that 10 sessions of VRET or PE will successfully treat PTSD, therapeutically affect levels of physiological arousal, and significantly reduce perceptions of stigma toward seeking behavioral health services.

The rationale for this study is based on growing evidence demonstrating that VRET is an efficacious treatment for PTSD and holds the potential to improve access to care for Soldiers who would otherwise avoid treatment. Although PE is considered one of the most effective cognitive-behavioral therapies (CBT) for treatments for PTSD, there are reasons why it may not be the most viable option for many Soldiers. First, prolonged exposure requires a level of emotional engagement during exposure to the trauma that many patients are unable to obtain. Second, stigma and concerns about how Soldiers will be perceived by peers and leadership has a dramatic impact on whether a Soldier will seek care. VRET may address these concerns and may also improve treatment outcomes and access to care by augmenting the patient's re-living of the trauma with a sensory-rich environment and moderating stigma perceptions by offering non-traditional treatment that is a preferable option for many Soldiers who are reluctant to seek out traditional talk therapies. Despite its promise as a viable treatment option, few studies have examined VRET for combat-related PTSD and there are no published studies that have compared VRET to PE in the treatment of combat-related PTSD. Positive results may provide new treatment options for all Soldiers, but should prove to be an especially attractive option for Soldiers who either do not respond to, or are reluctant to engage in other established therapies such as PE.

Eligibility Criteria:
Inclusion Criteria:

* PTSD diagnosis as assessed by CAPS
* history of deployment in support of Operation Iraqi Freedom/ Operation Enduring Freedom(OIF/OEF)
* non sexually based deployment related trauma
* three or more months since index trauma
* stable on psychotropic medication for 30 days

Exclusion Criteria:

* index trauma in the last three months
* history of schizophrenia, other psychotic or bipolar disorder
* history of organic brain disorder
* suicidal risk or intent or self-mutilating behavior requiring hospitalization in the last 6 months
* ongoing threatening situation
* current drug or alcohol dependence
* history of seizures
* prior history of PE for PTSD
* other current psychotherapy
* physical condition that interferes with proper use of Virtual Reality head mounted display
* history of loss of consciousness since entering active duty service greater than 15 minutes history of schizophrenia, other psychotic or bipolar disorder
Hip Fracture in Individuals Under 60 Years of Age

This study prospectively analyses and describes a cohort of non-elderly hip fracture patients at four orthopaedic departments in two Scandinavian countries regarding epidemiology, treatment, Patient Reported Outcome Measures, functional outcome as well as clinical results.

Hip fracture is common and well studied in the elderly population, but quite rare in the non-elderly and scarcely investigated in the literature. This prospective observational study focuses on individuals between 18 and 59 years old who have incurred a hip fracture and been treated at any of the participating orthopaedic departments in Sweden or Denmark. The study group is analysed and described at the time of the fracture and are followed during two years.

The patients' treatment follows the departments' standard rationale, there is no intervention in the study. Patients are included, after being informed and consent to participate is given, at the ward when they are admitted at the time of the fracture. The study comprises written enquiries (Patient Reported Outcome Measures, PROM) regarding hip- and global health before the fracture as well as interview and medical files and x-ray information regarding previous illness and use of medication, information about the injury, fracture type and treatment. Blood samples are used to investigate possible comorbidities and evaluate the hormonal and nutritional status and dual energy x-ray absorptiometry (DXA) is analysed with regards to reduced bone mineral density (osteopenia/-porosis). For patients with a femoral neck fracture who are treated with osteosynthesis, MRI with metal reduction is performed post-operatively and at 4 and 12 months to assess fracture healing and avascular necrosis of the femoral head.

Patients are followed up at 6 weeks by written PROM-enquiries by mail, and at 4, 12 and 24 months post-operatively with x-ray and visits in the outpatient clinic.

Eligibility Criteria:
Inclusion Criteria:

* Acute non-pathologic hip fracture regardless of trauma energy level or previous medical conditions.

Exclusion Criteria:

* Fracture older than four weeks.
* Not able to follow up, e.g. not living in the department area.
Novamin on Streptococcus Mutans Count in Dental Plaque of High Caries Risk Children

Inhibition of streptococcus mutans can be effective to prevent caries in high caries-risk children. The aim of the study is to evaluate the effect of Novamin on streptococcus mutans in the plaque of high caries-risk children.


Eligibility Criteria:
Inclusion Criteria:

* Medically healthy children.
* No erupting first permanent molars.
* High caries risk children; Have visible cavities or have a visible plaque on their teeth.
* Cooperative (Positive or definitely positive), according to Frankl's Behavior Rating Scale

Exclusion Criteria:

* History of intake of antibiotics for the past 3-4 weeks.
* History of professional fluoride treatment over 2 weeks before the study.
* Children with tooth structure defects.
* Children unable to return for recall visits
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months

Exclusion Criteria:

* Pregnant and breastfeeding women
* Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
Development and Validation of a Morbidity Index for Complications in Minor and Major Abdominal Surgery

The aim is to develop and validate a morbidity index for postoperative complications in patients undergoing visceral surgery.


Eligibility Criteria:
Inclusion Criteria:

* Age: ≥ 18 years
* Capacity to act and no legal guardian
* Patients with any underlying disease admitted to the Department of Visceral and Transplantation Surgery of the University Hospital of Zurich with planned minor or major visceral surgery
* German language as daily language.

Exclusion Criteria:

* Patients with cognitive difficulties and diseases, which may yield unreliable answers
* Patients unable to read and write
Study of the Anatomical Direct Insertion Anterior Cruciate Ligament Reconstruction

The purpose of the study is to study the effect of anatomical direct insertion ACL reconstruction compared with conventional anatomical ACL reconstruction.

The investigators divide 320 patients with ACL rupture into 4 groups, each group has 80 patients. The operation technique is different among the groups: group A: conventional anatomical double bundle acl reconstruction, group B: conventional anatomical single bundle acl reconstruction, group DA: direct insertion double bundle acl reconstruction, group DSB: direct insertion single bundle acl reconstruction. The investigators compare the results of the patients of each group at 2 years of surgery.

Eligibility Criteria:
Inclusion Criteria:

* ACL rupture patients aged between 16 to 40 years

Exclusion Criteria:

* combined severe injuries to the operated knee (additional ligament rupture, major meniscus loss, patella instability, cartilage damage \>2°, pathologic leg axis deviation)
* any injury or surgery to the contralateral knee
* any infammatory or systemic disease, neuromuscular disease in the lower limbs, any recent knee infection
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.

The study consists of two phases, the first stage is the exploratory stage of blood collection point which is the appropriate effective time after chemotherapy, radiotherapy, targeted therapy. The second phase, which is the expansion of the first phase, is to determine the precise leading time of ctDNA relative to tumor biomarkers or image evaluation in determining the efficacy of advanced NSCLC cancer therapy. Both stages were divided into three subgroups: the chemotherapy group, the radiotherapy group, and the targeted therapy group.

Eligibility Criteria:
Inclusion Criteria:

1. Greater than 18 years old;
2. Patients with stage III-IV NSCLC;
3. Have the tissue specimens (fresh or wax blocks) before this treatment;
4. PS\<=2 in radiotherapy/ chemotherapy group; PS\<=3 in targeted therapy group
5. Signing informed consent;

Exclusion Criteria:

1. Multiple primary lung cancer;
2. Incorporating any unstable systemic disease;
3. Histology is not NSCLC;
4. Unqualified blood samples;
5. Patients lacking any one of the detection points.
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease

This is the first clinical research trial in which intravenous Prostaglandin E1 (PGE1 is a vasoactive hormone) will be used as supportive treatment along with the angioplasty procedure to treat or open up a blocked artery within one lower limb or the most affected of two limbs in subjects with Peripheral Arterial Occlusive Disease.

PAOD results in a decrease in arterial blood flow to the lower limb and feet with symptoms that can include, pain at rest, a numbing sensation in limb or feet, limited ability to walk before pain occurs. PAOD can occur along with diabetic ulcers.

Proposed treatment will be given at a medical center with an overnight hospital stay. Treatment includes angioplasty to open up one or two occluded arteries in a lower limb plus a drug (Liprostin) a special formulation of liposomal Prostaglandin E1,or PGE1, a natural occuring vasoactive hormone). Drug treatment is given twice to each artery to be treated, just before and after angioplasty. When angioplasty procedure is completed, a 12 hour intravenous infusion of Liprostin is given to complete the treatment procedure.

A total of 12 PAOD subjects will be enrolled in a single center: Memorial Hermann Hospital, Houston, TX.

Study will begin in February, 2003 with the last (12th) subject to be enrolled, likely by August, 20

Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects, 18 years and older
* Diagnosis of Peripheral Arterial Occlusive Disease \[PAOD\]
* Subject is a candidate for immediate angioplasty of the lower limb
* Subject must complete 2 treadmill tests at Screen in which walking distance is limited by PAOD and not due to angina or fatigue

Exclusion Criteria:

* Lower limb peripheral re-vascularization procedures in past 3 months
* History of myocardial infarction in the past 6 months
* Malignant disease, uncontrolled hypertension or Class III heart failure
* Aortic occlusion, thrombosed popliteal aneurysm, severe hemorrhagic disorder, or a long iliac occlusion
Effects of Elastic Tape on Pulmonary Rehabilitation of Patients with Chronic Obstructive Pulmonary Disease

Evaluate the effect of the use of elastic tape in chest wall and abdomen in the physical capacity, psychosocial distress levels, quality of life and anxiety, and depression symptoms of individuals with moderate to very severe chronic obstructive pulmonary disease (COPD) undergoing pulmonary rehabilitation.

Individuals will be evaluated on two non-consecutive days (7 days apart). On the first visit, wil be obtained: clinical and anthropometric data and assessed clinical control \[COPD Assessment Test™(CAT)\], health-related quality of life \[Chronic Respiratory Questionnaire (CRQ)\], and anxiety and depression levels \[Hospital Anxiety and Depression Scale (HADS)\]. Patients will also perform a complete pulmonary function test. After, the volunteers will receive a triaxial accelerometer to assess their physical activity level (PAL) and will be instructed to return after seven days. On the second visit, patients will undergo the Incremental Shuttle Walking Test (ISWT), and the Endurance Shuttle Walking Test (ESWT), without ET.

After the assessments, the individuals will be randomized. Randomization will be computer generated (www.randomization.com) by an investigator who will not be involved in individual recruitment, evaluation, or intervention. The allocation of individuals will be secret using consecutive numbered, sealed, and opaque envelopes (concealed allocation). Initial and post-intervention assessments will be performed by an investigator who will not be involved in the recruitment, evaluation, or intervention. After inclusion, individuals will start a pulmonary rehabilitation (PR) program for eight weeks; twice a week, individuals in the ET group will have the tape applied at the beginning of each session and removed at the end. After completing the 8-week PR period, individuals will undergo the same tests performed in two visits.

Eligibility Criteria:
Inclusion Criteria:

* Moderate to very severe COPD diagnosis according to Global Iniciative for Chronic Obstructive Lung Disease (GOLD) 2020
* Clinical stability (i.e., no exacerbations for at least 30 days)
* Male
* Non-obese (BMI ≤29.9 kg/m2)
* No musculoskeletal limitation
* Not included in a pulmonary rehabilitation program in the last 6 months.
* Do not perform home oxygen therapy

Exclusion Criteria:

* Present osteoarticular, cognitive, neurological, and/or cardiological dysfunctions that prevent physical training
Mobile Technology for Blood Pressure Management

The primary objective of this study is to assess the feasibility and effectiveness of a mobile-technology based system that integrates patient-facing and clinician-facing components to assist the management of hypertension.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older with an established diagnosis of essential hypertension

Exclusion Criteria:

* Patients on more than 2 antihypertensives at time of enrollment
* Clinical diagnosis of secondary hypertension, that is, hypertension due to a secondary cause, including but not limited to the following:
* Renal artery stenosis
* Primary hyperaldosteronism
* Cushing syndrome
* Coarctation of the aorta
* Drug-induced hypertension
* Pheochromocytoma
* Obstructive sleep apnea
* Hospitalization for malignant hypertension or severe hypertension (including stroke, cardiac events, acute kidney injury) in the preceding 6 months
* Hospitalization for unstable angina or myocardial infarction in the preceding 6 months
* Prior diagnosis of heart failure or cardiomyopathy
* Stroke or transient ischemic attack within prior 6 months
* Prior organ transplantation
* Failure to obtain informed consent
* Pregnant or currently trying to become pregnant
* Patients who are enrolled in other research studies